NSCLC immunization ‘proof of concept’ achieved
Immunization against MAGE-A3 is a feasible adjuvant treatment in patients with resectable non-small-cell lung cancer expressing the tumor-specific antigen, research suggests.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine